New polymorph of tofacitinib citrate and in vitro equivalence study of its sustained-release tablets
PLOS One · 2025
DOI: 10.1371/journal.pone.0332664 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Yan Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, People's Republic of China. Hauptthemen laut MEDLINE: Piperidines, Pyrimidines, Pyrroles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Plan Project of Taizhou.
Abstract (Originalsprache)
Tofacitinib citrate (TOC) is clinically used primarily for the treatment of moderate to severe rheumatoid arthritis in patients who are intolerant or inadequately responsive to methotrexate. In this study, a new polymorph of TOC (form II) was prepared using solvent crystallization. The currently marketed form I and the self-prepared form II were characterized by XRD, DSC, FT-IR, and SEM, confirming that form II is a new polymorphic form of TOC. This new polymorph was then used in the development of TOC sustained-release tablets. In the formulation design, mannitol with low hygroscopicity was used to replace sorbitol. By adding a certain amount of microcrystalline cellulose to the tablet core and maintaining the mannitol content between 60 ~ 70% of the total core weight, an in vitro dissolution behavior similar to that of the reference formulation ( f 2 > 50) was achieved. This indicates that replacing sorbitol with mannitol as the osmotic agent in the osmotic pump tablet core is a practical and effective method. Additionally, key preparation processes for the TOC sustained-release tablets were investigated. The results suggest that the coating weight gain of the self-prepared sustained-release tablets should be controlled between 6% and 7%, and the suitable range for laser-drilled orifice diameter is 0.55 ~ 0.90 mm.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, People's Republic of China.
- School of Pharmacy, Taizhou University, Taizhou, People's Republic of China.
ORCID-Profile: Yan Wang, Dongkai Wang
Förderung
- Science and Technology Plan Project of Taizhou
Zitieren
APA
Wang, Y., Wen, S., Zhao, Y., Gui, L., Mou, Y., & Wang, D. (2025). New polymorph of tofacitinib citrate and in vitro equivalence study of its sustained-release tablets. PLOS One. https://doi.org/10.1371/journal.pone.0332664
Vancouver
Wang Y, Wen S, Zhao Y, Gui L, Mou Y, Wang D. New polymorph of tofacitinib citrate and in vitro equivalence study of its sustained-release tablets. PLOS One. 2025. doi:10.1371/journal.pone.0332664
BibTeX
@article{Wang2025,
author = {Wang, Yan and Wen, Shuai and Zhao, Yao and Gui, Lijuan and Mou, Yi and Wang, Dongkai},
title = {New polymorph of tofacitinib citrate and in vitro equivalence study of its sustained-release tablets},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0332664}
}
EUVIMED